Opsona Receives Milestone Payments Under Wyeth Collaboration
Dublin, Ireland -15 May 2008
Opsona Therapeutics has today announced the receipt of its first research milestone payments under its agreement from Wyeth Pharmaceuticals,a division of Wyeth (NYSE: WYE).
The collaboration is focused around the role of Toll-like Receptors (TLRs) in inflammation and has been progressing to plan since its inception in January 2006. The companies are working together to identify new compounds for chronic inflammatory diseases, with significant progress being made on the key projects and targets.
Professor Luke O’Neill, a founder of Opsona, explains that “Working together with Wyeth, we have identified key tools to aid in a structured drug discovery platform, which has provided an opportunity for Opsona to accelerate its potential in this field. ”
About Opsona
Opsona is a drug development company, focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company was founded in 2004 as a Trinity College campus company, with three of Trinity’s respected Immunologists. The company is specifically interested in the fields of the innate immune system, specifically Toll-Like Receptors (TLR). Opsona has a pipeline of new therapeutics in advanced pre-clinical development which modulate the innate immune system. Opsona is working on a variety of approaches to modulating the immune system, including biologics, peptides and small molecules. The company has signed some significant partnering and collaborative deals, such as Wyeth (USA) and Phylogica (Au).
The company is based at the Trinity Centre for Health Sciences at St James’ Hospital, Dublin.
www.opsona.com
For further information, please contact:
Dr Mark Heffernan, CEO
Tel: +353 (1) 896 8499
Email: info@opsona.com
Dr Jeremy Skillington,
Senior Director of Business development
Tel: + 353 1 8968499
Email: info@opsona.com